Zelos Therapeutics Inc. raised $42.5 million in a Series B round to fund clinical trials of its next-generation parathyroid hormone (PTH) analogue in four indications. (BioWorld Today)

Zelos' Series B Round Nets $42M For PTH Drug Pipeline

May 19, 2005

By Jennifer Boggs

Zelos Therapeutics Inc. raised $42.5 million in a Series B round to fund clinical trials of its next-generation parathyroid hormone (PTH) analogue in four indications. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...